Company Description
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 1958 |
| IPO Date | Mar 27, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 16,000 |
| CEO | Bernard Zovighian |
Contact Details
Address: One Edwards Way Irvine, California 92614 United States | |
| Phone | 949 250 2500 |
| Website | edwards.com |
Stock Details
| Ticker Symbol | EW |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001099800 |
| CUSIP Number | 28176E108 |
| ISIN Number | US28176E1082 |
| Employer ID | 36-4316614 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Bernard J. Zovighian | Chief Executive Officer and Director |
| Scott B. Ullem | Corporate Vice President and Chief Financial Officer |
| Donald E. Bobo Jr. | Corporate Vice President of Strategy and Corporate Development |
| Daveen Chopra | Corporate Vice President of Transcatheter Mitral and Tricuspid Therapies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2026 | ARS | Filing |
| Mar 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2026 | 144 | Filing |
| Mar 11, 2026 | 144 | Filing |
| Feb 26, 2026 | 144 | Filing |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 144 | Filing |